Combined Analysis of Phase I and Phase II Data to Enhance the Power of Pharmacogenetic Tests

Abstract : We show through a simulation study how the joint analysis of data from phase I and phase II studies enhances the power of pharmacogenetic tests in pharmacokinetic (PK) studies. PK profiles were simulated under different designs along with 176 genetic markers. The null scenarios assumed no genetic effect, while under the alternative scenarios, drug clearance was associated to 6 genetic markers randomly sampled in each simulated dataset. We compared penalised regression Lasso and stepwise procedures to detect the associations between empirical Bayes estimates of clearance, estimated by nonlinear mixed effects models, and genetic variants. Combining data from phase I and phase II studies, even sparse, increases the power to identify the associations between genetics and PK due to the larger sample size. Design optimisation brings a further improvement, and we highlight a direct relationship between η-shrinkage and loss of genetic signal.
Liste complète des métadonnées

http://www.hal.inserm.fr/inserm-01312316
Contributeur : Thu Thuy Nguyen <>
Soumis le : jeudi 5 mai 2016 - 17:32:25
Dernière modification le : mercredi 16 mai 2018 - 11:23:07
Document(s) archivé(s) le : mardi 15 novembre 2016 - 21:58:54

Fichiers

psp412054-1.pdf
Fichiers éditeurs autorisés sur une archive ouverte


Identifiants

Citation

Adrien Tessier, Julie Bertrand, Marylore Chenel, Emmanuelle Comets. Combined Analysis of Phase I and Phase II Data to Enhance the Power of Pharmacogenetic Tests. CPT: pharmacometrics & systems pharmacology, 2016, 5 (3), pp.123-31. 〈http://onlinelibrary.wiley.com/doi/10.1002/psp4.12054/abstract〉. 〈10.1002/psp4.12054〉. 〈inserm-01312316〉

Partager

Métriques

Consultations de la notice

141

Téléchargements de fichiers

196